A wealth of experimental data points to immunological and environmental factors in the pathogenesis of inflammatory bowel disease (IBD). Here we study the role of IL-23, the microbiome, and the diet in the development of colitis. To promote IL-23 expression in vivo,
INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC) are two distinct phenotypic patterns of inflammatory bowel disease (IBD) affecting over 1.5 million people in Europe and almost one million people in North American 1 . At the turn of the 21st century, IBD has become a global disease with newly industrialized countries now facing rising incidence, analogous to trends seen in the western world during the latter part of the 20th century 2 . Inflammatory bowel disease is associated with morbidity, mortality, and substantial costs to the health-care
system. Both CD and UC are characterized by periods of asymptomatic remission interrupted by episodes of symptomatic disease flares or exacerbations. While its exact cause is unknown, IBD seems to be due to a combination of genetic predisposition and environmental factors [3] [4] [5] [6] . Genome-wide association studies identified polymorphisms in several genes, including in the Interleukin-23 (IL-23) receptor (IL-23R) 7, 8 . IL-23 is a heterodimeric cytokine formed by the IL-23-specific p19 subunit and the IL-12p40 subunit. IL-23 interacts with cells that co-express the IL-23R subunit and the shared IL-12R β1 chain 9 . A number of cell types have been described as IL-23R positive and IL-23 responsive, including Th17 cells, gdT cells, macrophages, dendritic cells (DC), and innate lymphoid cells (ILC) 10, 11 .
Several experimental models support a role for IL-23 in colitis. Loss-of-function studies
show that IL-23p19 is essential for chronic colitis development in IL-10 -/-spontaneous colitis model 12 , CD45RB hi CD4 + T-cell transfer models 13 , Helicobacter hepaticus-driven colitis 14 , anti-CD40-induced acute innate colitis model 11, 15 , and chemically induced colitis 16 . Furthermore, recent evidence implicates IL-23-responsive Th17 cells and ILCs in colitis 11, 15 , but the function of cytokines downstream of IL-23 (e.g. IL-17, IL-22) is still controversial. Other studies show that IL-23R expression by CD4 + T cells is required for disease development in murine T-cell transfer colitis model 17 and that IL-23R expression by ILCs is important for colitis development in an anti-CD40 antibody-induced acute innate colitis model 15 18 . Dietary changes have been proposed as a key factor in the increasing incidence of IBD in developing nations. Several large longitudinal studies have pointed to a lower risk of IBD among people who consume more fruits and vegetables, and a higher risk in people who consume less of these and more animal fats and sugar 19 . Consumption of specific foods has also been associated with CD and UC flares 19 . In mice, the contribution of specific genes and the microbiota to colitis has been extensively analyzed. Mice bearing specific gene alterations develop colitis, but a significant number of them do not develop colitis when raised in germ-free conditions, suggesting a critical role for genes and the microbiota in promoting disease 4, 20 . Other animal studies suggest a critical role of dietary components in the onset and severity of colitis [21] [22] [23] . Yet, the development of relapsingremitting disease models has not been reported. Because of this limitation it has been difficult to evaluate the contribution of diet and microbiota changes to disease initiation and progression.
To examine the contribution of IL-23, the microbiota and diet to development of colitis, we Figure S1 . All the germ-free (GF) mice were bred inhouse and housed in standard flexible film isolators in our GF animal facility. All animal experiments in this study were approved by the Institutional Animal Care and Use
Committee of Icahn School of Medicine at Mount Sinai, and were performed in accordance with the approved guidelines for animal experimentation at the Icahn School of Medicine at Mount Sinai.
Diet Treatment
All mice were raised on the basal diet 5053, which was purchased from LabDiet (St. Louis, MO). The basal diet 2019 (TD. 160647) was purchased from Envigo (Madison, WI). Tamoxifen (500mg/kg) (Sigma) was added to the Envigo diet 2019 (TD. 130968). R23FR mice and control FR mice were fed with tamoxifen diet during the indicated times shown as Figure 1A .
After each cycle of TAM treatment, animals were switched back to the basal diet 5053.
Quantification of Fecal Lcn-2 by Enzyme-linked Immunosorbent Assay (ELISA)
Freshly collected or frozen fecal samples were reconstituted in PBS containing 0.1% Tween 20 (100 mg/ml) and vortexed for 20 min to get a homogenous fecal suspension 26 . These samples were then centrifuged for 10 min at 12,000 rpm and 4°C. Clear supernatants were collected and stored at −20°C until analysis. Lcn-2 levels were estimated in the supernatants using Duoset murine Lcn-2 ELISA kit (R&D Systems, Minneapolis, MN). 
Flow Cytometry and Sorting
Cell suspensions from the lamina propria and mLN were prepared as described previously 27 .
All cells were first pre-incubated with anti-mouse CD16/CD32 Cells were > 95% pure after sorting. The sorted cells were used for TCR sequencing.
T cell Purification
For CD4 + T-cell isolation, mLNs and large intestine were digested in collagenase as described previously 27 . CD4 + T cells were enriched by positive immunoselection using CD4-(L3T4) microbeads (Miltenyi Biotec). The magnetic-activated cell sorting (MACS) purified CD4 + T cells were used as donor cells in adoptive transfer experiments.
Histology
Tissues were dissected, fixed in 10% phosphate-buffered formalin, and then processed for paraffin sections. Five-micrometer sections were stained with hematoxylin and eosin (H&E) for histological analyses. All the sections were evaluated for a wide variety of histological features that included epithelial integrity, number of goblet cells (mucin production), stromal inflammation, crypt abscesses, erosion, and submucosal edema. Severity of disease was then classified based on a modified version of the Histologic Activity Index as described before 28 . Briefly, the disease score in the large intestine was calculated as follows: grade 0:
absence of epithelial damage, focal stromal inflammation or regenerative changes; grade 1:
crypt abscesses in less than 50% of the epithelium. Diffuse stromal inflammation and/or regenerative changes; grade 2: crypt abscesses in more than 50% of the epithelium and focal erosion or cryptic loss. Diffuse and accentuated crypt distortion with stromal inflammation; grade 3: Pan-colitis, diffuse erosion and ulcers.
Microbiota Transplantation
Cecal extracts pooled from 3-5 donor SPF mice were suspended in PBS (2.5 ml per cecum) and were administered (0.1 ml per mouse) immediately to R23FR and FR germ-free mice that were generated in house 29 . Transplanted mice were maintained in separate filter-top gnotobiotic cages and two weeks after were used for the further experiments 30 .
DNA Extraction, 16S rDNA Amplification, and Multiplex Sequencing DNA was obtained from feces of mice using a bead-beating protocol 31 . Briefly, mouse fecal pellets (~50 mg), were re-suspended in a solution containing 700μL of extraction buffer Cells were then mechanically disrupted using a bead beater (BioSpec Products, Bartlesville, OK; maximum setting for 5 min at room temperature), followed by extraction with QIAquick 96 PCR Purification Kit. Bacterial 16S rRNA genes were amplified using the primers as described in Caporaso et al 32 . Sample preparation and analysis of 16S rDNA sequence were done as previously described 33 . The 16S rDNA data were analyzed with MacQIIME 1.9.1. OTUs were picked with 97% sequence similarity and the sequences were aligned to the Greengenes closed reference set with a minimum sequence length of 150bp and a minimum percent identity of 75% 34, 35 .
Antibiotic Treatment
For reduction of the intestinal microbiota, a 'cocktail' of antibiotics containing ampicillin 1g/L, metronidazole 1g/L, neomycin 1g/L, and vancomycin 0.5g/L (Sigma Aldrich) in the drinking water was provided to the mice through their drinking water. Antibiotic treatment was renewed every week.
Reverse-transcription Polymerase Chain Reaction
Total RNA from tissues/sorted cells was extracted using the RNeasy mini/micro Kit (Qiagen) according to the manufacturer's instructions. Complementary DNA (cDNA) was generated with Superscript III (Invitrogen). Quantitative PCR was performed using SYBR Green Dye (Roche) on the 7500 Real Time System (Applied Biosystems) machine. Thermal cycling conditions used were as follows: 50 °C for 2min and 95 °C for 10 min, 40 cycles of 95 °C for 15 s, 60 °C for 1min, followed by dissociation stage. Results were normalized to the housekeeping gene Ubiquitin. Relative expression levels were calculated as 2 (Ct(Ubiquitin)-Ct7) .
Primers were designed using Primer3Plus 36 .
In Vivo Antibody Treatment 
T cell Adoptive Transfer
One million CD4 + from mLN and/or large intestine enriched by using MACS-beads (Miltenyi Biotech) were transferred into Rag1 -/-recipient mice by intravenous (i.v.) injection.
Bulk Sequencing of TCRs
Briefly, cells were suspended in Trizol (Invitrogen) and total RNA was isolated. Using poly T beads, mRNA was isolated and fragmented briefly to generate 600-800bp fragments by using mRNA-seq kit (Bioo Scientific Corporation). Each of these RNA fragments were then converted to double stranded cDNA using random primers, end repaired and an A base added to each 3'end of the fragment. Two universal DNA sequences (A and B) (compatible with Illumina sequencing instruments) were ligated to each end of the fragment respectively. To enrich the library for T cell receptor transcripts, two sets of PCR reactions were performed. The first PCR reaction was done using a primer complementary to the Constant region and the universal sequence A. The second, nested PCR was performed using another constant region primer and universal sequence A. In the end Illumina compatible amplicons were generated with greater than 90% specificity to the T cell receptor transcripts.
The unique molecular indexes (UMID) in the sequenced reads were used to remove PCR duplicates and the reads were mapped to annotated V and J segments, which are compiled 
RESULTS

IL-23 Expression Induces An Inflammatory Disease that Resembles UC in Humans
Although were fed the conventional diet used in our mouse facility (diet 5053, Lab Diet) ( Figure 1A ). To monitor inflammation in a non-invasive way we measured the levels of Lipocalin 2 (Lcn-2) in the stools 26 . The levels of fecal Lcn-2 varied during treatment of R23FR mice ( Figure 1C ), but not FR mice ( Figure 1C ), suggesting that expression of IL-23 induced inflammation.
Histological evaluation of the gut was performed next, at the time points specified in Figure   1A . The small intestine of the R23FR mice appeared normal and did not show infiltrates at the time points examined. The cecum and colon of R23FR mice at d7 did not present inflammatory infiltrates ( Figure 1B) . However, by day 21 we observed the presence of leukocytic infiltrates in the mucosa of colon and cecum of R23FR mice ( Figure 1B ). In the colon, the presence of crypt abscesses was noted, but no erosions were observed ( Figure 1B) . Many genetically susceptible animals do not develop colitis when raised in germ-free conditions 4 . To test if microbes were required in our model, we developed a gnotobiotic colony of R23FR mice and FR mice, and treated them with the same protocol used for SPF mice (Fig 1) . In striking contrast to the SPF R23FR mice, none of the GF R23FR mice showed inflammation in the cecum and colon at d56 (Supplementary Figure 7A) . Next we asked if colonization of GF mice with commensal bacterial would be sufficient to cause disease. We found that introduction of C57BL/6 microbiota into GF FR mice did not cause disease, but that it caused colitis in GF R23FR mice (Supplementary Figure 7B) . We then performed experiments to test whether different donor microbiota could induce disease (Supplementary Figure 8A) . Transfer of SPF R23FR microbiota into GF R23FR recipient promoted disease, but this flora was not sufficient to cause disease when transferred into GF FR mice (Supplementary Figure 8B) . No disease was observed in GF FR mice that received FR SPF microbiota (Supplementary Figure 8B) . Transplant of the microbiota of SPF R23FR mice into FR mice did not cause disease suggesting that the R23FR microbiota at peak disease is not sufficient to induce disease and requires co-expression of IL-23. Together, these results indicate the microbiota is a key factor contributing to IL-23-induced colitis.
Development of Relapse is Dependent on the Diet-modified Microbiota
Having established a critical requirement for the microbiota in disease development, we tested next if the induction of relapse induced by the diet switch required microbes. To do so, we treated R23FR mice and FR mice with 2 cycles of TAM and then with an antibiotic cocktail (ampicillin metronidazole, neomycin, vancomycin) from d35 to d56 ( Figure 3A ). All Antibiotic treatment significantly reduced colitis severity in the R23FR mice that received the diet 2019 from days 49-56 ( Figure 3B-3C ). These results further implicate the microbiota in the development of the diet-induced relapse.
To examine if the diet changes promoted changes in the composition of the microbiota we performed a longitudinal study with R23FR and FR mice. We collected fecal samples for microbiota analysis at different time points (d49, d51, d53 and d56, d58 and d63) ( Figure   4A ), and evaluated disease by histology ( Figure 4B ). Cecum inflammation was not observed in animals at d49. Diet switch promoted colitis in 2/11(~18%) of the animals at d51, 5/11(~ 46%) of the animals at d53 and 10/11 (~91%) of the animals at d56 ( Figure 4B ). There was an increase not only in penetrance but also in severity of the disease during this time ( Figure   4B ). Analysis of the microbiome during this period revealed that there was a significant reduction in alpha diversity (a measure of overall microbiome diversity) in both groups as early as 4 days after the diet switch (d53). A very pronounced difference was observed between groups at d56 ( Figure 4C ). Further analysis showed that there were no significant taxa differences between R23FR and FR mice at d49 (prior to treatment), indicating that changes in diversity were not due to pre-treatment differences in the microbiome ( Figure   4D ). However, by d51, two days after diet switch, there was a significant expansion of
Verrucomicrobia and a decrease of Bacteroidetes compared with day 49 in both R23FR and FR groups ( Figure 4D and Supplementary Figure 9 ). Similar changes were found at d53 and d56
( Figure 4D and Supplementary Figure 9 ). At d56 there was a significant difference in the relative abundance of Proteobacteria in R23FR mice compared to FR mice, which coincided with peak inflammatory disease ( Figure 4D and Supplementary Figure 9 ). Re-conversion to the 5053 diet (d58 and d63) resulted in rapid restoration of the microbiota to pre-treatment levels (d49) ( Figure 4D ). These results indicate that diet switch promoted significant changes in the microbiota of both R23FR and FR groups of mice at the time points examined ( Figure 4D ). Overall, our results indicate that development of flares caused by diet switch is dependent on the intestinal microbiota, and that a diet switch can rapidly change the composition of the microbiota.
Lymphocytes Are Required for Intestinal Inflammation
To examine the number and type of leukocytes present in the large intestine during disease Given the significant changes in the numbers of lymphocytes (Supplementary Figure 10B and C) observed in the LI of the R23FR mice and relevance of these cells to pathogenesis in experimental models, we tested next whether they were required for disease. To do so, we crossed R23FR mice with Rag deficient (Rag -/-) mice, which lack B and T cells, to generate R23FR/Rag -/-mice and subjected them to the protocol described in Figure 2A . Disease was completely absent in R23FR/Rag -/-mice, as determined by histological analysis of the large intestine ( Figure 5A & 5B). These results indicated that lymphocytes were required for disease. To discriminate between the major lymphocyte populations causing disease, we crossed R23FR mice into muMt -/-mice, which lack B cells. By the end of third cycle of TAM treatment, we observed similar histological scores for R23FR and R23FR/muMt -/-mice ( Figure   5A & 5B), suggesting that B cells were not required for disease.
CD4 + T Cells Are the Main Effector Cells Promoting Colitis Upon Diet Switch
Since our results strongly suggested that T cells were the effector cells promoting colitis, we examined next which type of T cells accounted for the disease in the R23FR mice. To do so we crossed R23FR mice into Tcrd -/-mice that lack gamma-delta T cells. R23FR/Tcrd -/-mice had a disease that was indistinguishable from that observed in R23FR/Tcrd +/+ mice ( Figure 5A & 5B), suggesting that TCRαβ T cells, not TCR gamma delta cells, were responsible for disease in the R23FR mice. To define which TCRαβ T cells were responsible for disease, we used antibodies to deplete CD4 + or CD8 + T cells ( Figure 5C and Supplementary Figure 11 ).
Depletion of CD4 + , but not CD8 + T cells significantly reduced disease severity ( Figure 5D) suggesting that CD4 + T cells had a critical effector role in this model. 
DISCUSSION
Here we show that low-level expression of IL-23 by CX 3 CR1 + cells triggered development of a colitis that was dependent on the microbiota and the diet, and that had a striking resemblance to human disease, with cycles of active disease (relapse or flares) followed by remission 38 . Expression of IL-23 resulted in the generation of a memory T cell population that was impacted by the microbiota, and had a skewed T cell repertoire. The colitogenic capacity of these T cells depended on the presence of a specific microbiota, which fluctuated in accordance to the diet.
IL-23 is a cytokine that has been implicated in the pathogenesis of several inflammatory conditions, including psoriasis, arthritis and IBD. Studies have shown that susceptibility to CD and UC is influenced by polymorphisms in the Il23r gene 7, 8 , and that elevated levels of IL- but not colon, and causes neonatal death 43 . Systemic exposure of adult animals to IL-23 via hydrodynamic delivery of plasmids encoding the IL-23 subunits results in rapid onset of psoriatic-like lesions in the ears, arthropathies in the paws and spine 44, 45 , adenomatous tumors in the proximal duodenum 46 , but not colitis. Here we show that IL-23 expression can lead to development of colitis; but that it requires simultaneous diet-driven changes in the microbiota to cause disease. These results add to the clinical evidence that targeting IL-23 through p40 (ustekinumab) 47 or more specifically anti-p19 antibodies (brazikumab and risankizumab) 48, 49 are effective in IBD.
The hypothesis that diet is an important factor contributing to the onset and progression of IBD, has remained formally unproven to date. Our results indicate that diet is a critical factor affecting development of IL-23-driven experimental IBD, and suggest that it does so by modifying the microbiota. Our studies showed a marked reduction in alpha diversity as function of the diet change.
These changes were already clear at d53 in both control and R23FR mice, and more pronounced at d56. Reduced diversity generally results in a reduced capacity of the microbial community to adapt to environmental pressures, and is likely to impact negatively on the microbial functional capacity 51 . The taxa composition was similar between the groups at days 51 and 53, but was different from that of the same animals before the diet switch. The most evident change induced by the diet switch was an increased abundance of to be derived from the bacteria, rather than from the diet. A food antigen would have triggered disease in the germ-free conditions, which was not observed here. However, factors other than bacterial antigens may also contribute to the overall immune response.
As immune cells are sensitive to the action of bacterial metabolites, it is possible that in addition to bacterial antigens, they may be also responding to bacterial or host derived metabolites 62 .
We A fundamental property of memory T cells is the ability to proliferate rapidly and elicit effector functions in response to secondary challenge 61, 64 . We suggest that IL-23 expression favors development of a memory T cell population that can become pathogenic upon diet switch. As such, IL-23 could contribute to a break in tolerance to antigens present in the commensal microbiota. Indeed, a break in tolerance to commensal antigens is thought to induce chronic intestinal inflammation in humans 65 . Increased expansion and skewing of T cells has been reported in patients with IBD 39, 66 and in the CD4 + CD45RB hi adoptive transfer mouse model 67 . The clonal expansion that we observed here in adoptive transferred Rag -/-mice fed with diet 2019 suggest that these expanded clones are pathogenic, but further studies are required to test this hypothesis.
In conclusion, we propose that IL-23 has a critical role in the generation of a CD4 + T cell primers F3 and R3 from untreated R23FR mice DNA, whereas a 500-bp fragment corresponding to the deleted allele was amplified from treated R23FR mice. (D) qPCR analysis of IL-23p19 and p40 mRNA expression from sorted YFP + (CX 3 CR1 + ) cells from large intestine of R23FR mice without or with TAM treatment for 7 days. Columns and bars represent mean ± s.e.m (*p<0.5; **p<0.01, Mann-Whitney test).
